Resource implications (e.g. cost of incontinence management methods) · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 5 to 15 years with dysfunctional elimination syndrome, 41/59 with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 3 to 18 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 5‐14 years with daytime urinary incontinence or post‐micturition dribbling
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 4 to 17 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 6 to 12 years with overactive bladder with urge incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prostatitis symptoms Subgroup: Intraprostatic injection, participants age > 50 years old, basal NIH‐CPSI score > 30 · participants with chronic prostatitis/chronic pelvic pain syndrome
1 finding from 1 review
Prostatitis symptoms Subgroup: Pelvic floor muscles injection, participants age < 50 years old, basal NIH‐CPSI score < 30 · participants with chronic prostatitis/chronic pelvic pain syndrome
1 finding from 1 review
Body image · adult women, 18 years of age or older, who tested positive for a pathogenic mutation in BRCA1 or BRCA2 and who had had risk‐reducing surgery
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
CBA: Average lost work time per 100 person‐years · workers
2 findings from 1 review
Cumulative cases of typhoid fever at 2 years · adults and children of 2 years of age and older
Vi‐rEPA vaccine (2 doses) probably leads to lower cumulative cases of typhoid fever at 2 years compared with control (moderate certainty).
2 findings from 1 review
Cumulative cases of typhoid fever at 2.5 to 3 years · adults and children aged 5 years of age and older
Ty21a vaccine (three doses) probably leads to lower cumulative cases of typhoid fever at 2.5 to 3 years compared with control (moderate certainty).
1 finding from 1 review
Cumulative cases of typhoid fever at 2.5 to 3 years · adults and children of 2 years of age and older
Vi polysaccharide vaccine (1 dose) may leads to lower cumulative cases of typhoid fever at 2.5 to 3 years compared with control (low certainty).
1 finding from 1 review
Intervention not reported
Spontaneous abortion/miscarriage · adolescent girls and women aged 15 to 45 years who became pregnant during the study
The intervention showed no clear difference in spontaneous abortion/miscarriage (high certainty).
1 finding from 1 review
Hospital usage (composite measure of ED, rehospitalisation) · all patients (aged > 18 years) at a transition of care
It is very uncertain whether medication reconciliation interventions changes hospital usage (composite measure of ED, rehospitalisation) compared with standard care (very low certainty).
1 finding from 1 review
Falls · adults (18 years of age or older at diagnosis) living with and beyond cancer
1 finding from 1 review
Late AMD · adults undergoing cataract surgery with IOL implantation
1 finding from 1 review
Intervention not reported
Serious adverse events Measured by: proportion of serious adverse events (total) Average study duration (range): not stated · children and adolescents aged 18 years and under diagnosed with ADHD
It is very uncertain whether the intervention changes serious adverse events Measured by: proportion of serious adverse… (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events Measured by: proportion of any serious adverse events Average study duration (range): 4.7 months (14 days to 21 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to serious adverse events (non‐comparative cohort studies) Measured by: proportion of participants withdrawn from treatment Average study duration (range): 7.9 months (1 month to 37 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review